Description:Oclacitinib is a selective Janus kinase (JAK) inhibitor primarily used in veterinary medicine, particularly for the treatment of allergic dermatitis in dogs. It works by modulating the immune response and reducing inflammation by inhibiting the activity of JAK enzymes, which play a crucial role in the signaling pathways of various cytokines and growth factors. The chemical structure of oclacitinib includes a pyrimidine ring and a phenyl group, contributing to its pharmacological properties. It is administered orally and has a favorable pharmacokinetic profile, allowing for effective absorption and distribution in the body. Oclacitinib is generally well-tolerated, but potential side effects may include gastrointestinal disturbances and changes in blood cell counts. Its use is regulated, and it is important for veterinarians to monitor patients for any adverse reactions during treatment. Overall, oclacitinib represents a significant advancement in the management of allergic conditions in dogs, providing relief from symptoms while minimizing the need for corticosteroids.
We use cookies to enhance your visit. We do not include advertising.
Please see our Cookies Policy for more details or adjust your preferences in "Settings".
This is the advanced settings system for our own and third-party cookies. Here you can modify parameters that will directly affect your browsing experience on this website. If you wish you may check the list of Cookie types.
Please note that disabling cookies can cause failures in the normal operation of the web.
![N-Methyl-1-(Trans-4-(Methyl(7H-Pyrrolo[2,3-D]Pyrimidin-4-Yl)Amino)Cyclohexyl)Methanesulfonamide](https://static.cymitquimica.com/products/54/thumb/OR1026277.jpg)
